Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Vertex Corp. (5290.TO) Japan 1st Quarter Ended June 30 GROUP 2025 2024 Revenue Y8.70 bln Y8.24 bln Operating Profit Y1.08 bln Y781.00 mln Pretax Profit Y1.15 bln Y830.00 mln Net Profit Y658.00 mln ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...

Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...

The heritage British brand has been revived by a chairman whose impressive career before watchmaking includes a three-year ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...